X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/celltrion-usa-completes-submission-of-biologics-license-application-bla-to-us-fda-for-ct-p39-an-interchangeable-biosimilar-candidate-of-xolair-omalizumab-302084902.html
https://www.reuters.com/business/healthcare-pharmaceuticals/roches-xolair-reduces-reactions-severe-food-allergies-study-2024-02-25/
https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976
https://www.biospace.com/article/novartis-nixes-phase-iii-peanut-allergy-trial-in-another-late-stage-flop-for-potential-xolair-successor-/
https://endpts.com/genentechs-food-allergy-medication-gets-priority-review-nod-from-the-fda/
https://www.globenewswire.com//news-release/2023/12/19/2798659/0/en/FDA-grants-priority-review-to-Xolair-omalizumab-for-children-and-adults-with-food-allergies-based-on-positive-National-Institutes-of-Health-phase-III-study-results.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976
https://endpts.com/genentech-to-start-construction-on-a-new-manufacturing-facility-in-california/
https://endpts.com/taking-aim-at-xolair-celldex-offers-a-positive-early-readout-for-their-rival-drug-but-researchers-have-a-lot-of-work-remaining/
https://www.fiercepharma.com/pharma/sanofi-regeneron-halt-trial-dupixent-vs-novartis-and-roche-s-xolair-for-hives
https://www.fiercebiotech.com/biotech/novartis-suffers-shock-setback-as-xolair-successor-fails-phase-3
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-14-2021-1626258357.pdf
https://endpts.com/aiming-to-rebound-from-blunders-years-ago-celldex-touts-a-phase-ib-win-with-sights-set-on-xolair/
https://www.raps.org/news-and-articles/news-articles/2021/4/fda-approvals-roundup-trodelvy-and-xolair
https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-of-xolair-omalizumab-self-injection-with-prefilled-syringe-across-all-indications-for-appropriate-patients-301266937.html
https://endpts.com/novartis-gets-breakthrough-designation-for-xolair-successor-setting-up-spotlight-for-phiii-readout-later-this-year/
http://www.pharmatimes.com/news/roches_xolair_gets_us_nod_for_nasal_polyps_1358818
http://www.pharmatimes.com/news/fda_accepts_application_for_self-administered_xolair_use_1346854
http://www.pharmafile.com/news/555619/novartis-xolair-scores-european-approval-treat-chronic-rhinosinusitis-nasal-polyps
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps
http://www.pharmatimes.com/news/could_prozac_help_fight_neuroblastoma_1321910
http://www.pharmatimes.com/news/novartis_abandons_asthma_drug_after_late-stage_failure_1320404
https://www.fiercebiotech.com/biotech/novartis-xolair-follow-up-banishes-hives-42-patients-chronic-hives
https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-novartis-pharmaceuticals-xolair-omalizumab-powder-for-solution-1568179166.pdf
https://www.fiercepharma.com/manufacturing/manufacturing-news-note-catalent-expands-hospira-and-novartis-recall-prodjects
https://www.fiercepharma.com/pharma/genentech-to-settle-biosimilar-trade-secret-theft-suit-taiwan-s-jhl
https://www.fiercepharma.com/pharma/sanofi-and-regeneron-s-dupixent-scores-third-fda-approval-sinusitis-nasal-polyps
https://www.fiercepharma.com/marketing/sanofi-and-regeneron-delves-deep-uncontrolled-asthma-digital-awareness-campaign
https://www.fiercepharma.com/pharma/novartis-xolair-looking-to-hold-blockbuster-status-positive-sinusitis-data
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976
https://endpts.com/novartis-plots-to-retain-hives-patients-with-monoclonal-antibody-that-outshines-xolair/
https://scrip.pharmaintelligence.informa.com/SC124179/ICER-On-Asthma-Biologics-5079-Price-Discounts-Needed-To-Meet-Value-Assessment-Metrics
https://www.fiercepharma.com/marketing/roche-novartis-grab-fda-ok-for-new-version-aging-blockbuster-xolair
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103976
https://endpts.com/genentech-vet-myrtle-potter-takes-a-leading-role-in-vivek-ramaswamys-fast-moving-vant-ops/
https://endpts.com/astrazeneca-writes-off-its-second-pivotal-copd-trial-for-fasenra-killing-expansion-plans/
Market Place
Share 
